First-in-Class Orexin Agonist Secures Global Approvals for Narcolepsy Type 1

ORZEYFUL (oveporexton), the first oral orexin receptor 2 agonist for narcolepsy type 1, has secured approvals in Japan, China, and the US. This marks a shift from symptom management to addressing the underlying orexin deficiency, offering significant improvements in excessive daytime sleepiness and cataplexy based on Phase 3 clinical trial data.

This development signals a new era in narcolepsy treatment, potentially improving patient quality of life by targeting the disease's root cause rather than just its symptoms.

Read the full article at Sleep Review

---

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.